The Imricor Medical Systems Inc (ASX: IMR) share price is in focus today after the company announced the commercial launch of its Interventional MR (iMR) lab solution in collaboration with global imaging leader Philips. This new combined solution is immediately available in CE-marked markets and is designed to support MR-guided cardiac interventions.
Image source: Getty Images
What did Imricor Medical Systems report?
- Commercial launch of a combined iMR lab solution with Philips.
- The solution integrates Philips' 1.5T BlueSeal MR platform with Imricor's NorthStar®, Advantage-MR®, and other systems.
- Includes Imricor's single-use catheters and interventional tools for cardiac procedures.
- Available immediately in CE-marked markets; select configurations in the US now and more pending regulatory approval.
- Scalable platform for potential expansion into new procedures and clinical areas.
What else do investors need to know?
The launch builds on Imricor's longstanding partnership with Philips, which began in 2012 with joint technology development. The iMR lab solution is designed specifically for cardiac electrophysiology and other interventional cardiac procedures, using MR-guided imaging for improved care.
This innovative, purpose-built approach aims to move MR imaging technology directly into the procedure room, making advanced interventions safer and more effective. The collaboration positions Imricor alongside a major industry player, broadening its reach and potential customer base.
What's next for Imricor Medical Systems?
Imricor plans to showcase the new iMR lab solution at the ESC Congress 2026 in Munich. The company expects further configurations to be launched in the United States and other geographies as regulatory clearances are achieved.
Management sees this launch as a foundation for future growth, with ambitions to expand the platform into new clinical areas beyond cardiac electrophysiology. The partnership with Philips could pave the way for increased adoption of MR-guided interventions globally.
Imricor Medical Systems share price snapshot
Over the past 12 months, Imricor shares have risen 39%, outperforming the All Ordinaries Index (ASX: XAO).
